• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease - 29 Studies Found

Completed : Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
: Oral Chronic Graft-versus-host Disease
: 2008-05-27
:
  • Drug: Tacrolimus Tacrolimus el

Withdrawn : Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease
: Active Chronic Graft Versus Host Disease
: 2009-10-26
: Drug: Pentostatin; Cyclophosphamide; Rituximab Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophospha
Active, not recruiting : Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
: Chronic GVHD
: 2010-04-16
:
  • Drug: Sirolimus + calcineurin inhibitor + prednisone

Completed : Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)
: Refractory Chronic Graft Versus Host Disease (cGVHD)
: 2015-01-14
: Device: Photopheresis Theraflex ECP™ The Macopharma (Theraflex ECP™) approach is based on a
Recruiting : Treatment of Chronic GVHD of Liver or Lungs by ECP
: Chronic Graft-Versus Host Disease
: 2006-01-03
: Procedure: Extracorporeal photoimmunotherapy
Completed : A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
: Chronic Graft Versus Host Disease
: 2025-08-03
: Pharmaceutical form:Tablet-Route of administration:oral
Completed : Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
: Chronic Graft Versus Host Disease
: 2025-08-03
: Given PO
NOT_YET_RECRUITING : Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
: Chronic Graft Versus Host Disease
: 2025-08-03
: 200mg PO QD x 24 cycles (28-day cycle)
COMPLETED : Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
: Chronic Graft Versus Host Disease
: 2025-08-03
: The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose l
<<< Previous
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.